Back to search

Article

Brief Report: Correlation cannot be used to compare sequencing panels used for the assessment of tumor mutational burden in non-small cell lung cancer

2020-03-30

Abstract excerpt

<h4>Introduction</h4> Tumor mutational burden (TMB) has been proposed as a novel predictive biomarker for the stratification of patients undergoing immune-checkpoint inhibitor (ICI) treatment in non-small cell lung cancer (NSCLC) patients. The assessment of TMB has recently been established using large targeted sequencing panels and numerous studies are ongoing to harmonize the TMB assessment. However, usually “co...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
5fe8dd28-d9de-59be-90c8-b361175503e0
DOI
10.1101/2020.03.28.20046102
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Brief Report: Correlation cannot be used to compare sequencing panels used for the assessment of tumor mutational burden in non-small cell lung cancerDOI 10.1101/2020.03.28.20046102
Comparison of Three Sequencing Panels Used for the Assessment of Tumor Mutational Burden in NSCLC Reveals Low Comparability.Semantic proximity
Evaluation of Prognostic Utility of Tumor Mutation Burden for NSCLC response to Immune Checkpoint Blockade Therapy: A Single Institute StudySemantic proximity
Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small Cell Lung CancerSemantic proximity
Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB2 harmonization project comparing three NGS panels.Semantic proximity
Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients.Semantic proximity
Leveraging non-coding regions to guarantee the accuracy of small-sized panel-based tumor mutational burden estimates.Semantic proximity
Designing gene panels for tumor mutational burden estimation: the need to shift from ‘correlation’ to ‘accuracy’Semantic proximity
HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors.Semantic proximity
Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routine.Semantic proximity
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.Semantic proximity
Harmonization of tumor mutation burden testing with comprehensive genomic profiling assays: an IQN Path initiative.Semantic proximity
Systematic assessment and optimizing algorithm of tumor mutational burden calculation and their implications in clinical decision-makingSemantic proximity
Select a neighboring publication to make it the new centre.